Giuseppe Ciaramella - 24 Feb 2026 Form 4 Insider Report for Beam Therapeutics Inc. (BEAM)

Role
President
Signature
By: /s/ Christine Bellon, Attorney-in-fact
Issuer symbol
BEAM
Transactions as of
24 Feb 2026
Net transactions value
-$525,042
Form type
4
Filing time
26 Feb 2026, 16:05:04 UTC
Previous filing
02 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Ciaramella Giuseppe President C/O BEAM THERAPEUTICS INC.,, 238 MAIN STREET, CAMBRIDGE By: /s/ Christine Bellon, Attorney-in-fact 26 Feb 2026 0001786322

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BEAM Common Stock Options Exercise $595,000 +35,000 +18% $17.00 225,216 24 Feb 2026 Direct
transaction BEAM Common Stock Sale $1,120,042 -35,000 -16% $32.00 190,216 24 Feb 2026 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BEAM Stock Option (Right to Buy) Options Exercise $0 -35,000 -8.1% $0.000000 397,313 24 Feb 2026 Common Stock 35,000 $17.00 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The shares of Common Stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2025.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $32.00 to $32.04, inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3 The option vests as to 25% on the first anniversary of the of the vesting commencement date, February 5, 2020, and at a rate of 2.78% each month thereafter until the option is fully vested.